|
|
42nd ICAAC 2002 - Biodefense and Emerging InfectionsPublished by: Datamonitor Published: Nov. 28, 2002 - 42 Pages Table of ContentsOverview Introduction The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) is the world's premier meeting on infectious diseases and antimicrobial agents, organized by the American Society for Microbiology. This Brief discusses some of the keynote lectures at the 42nd ICAAC 2002, focusing on emerging and re-emerging infections and the increasing threat of bioterrorism. Scope The key pathogens and bioterrorism threats are identified. Incentives for developing new products for biodefense are discussed. Emerging and re-emerging infections are profiled. Key commercial opportunities to develop and commercialize relevant products are identified. Report Highlights The Bioterrorism related pharmaceutical market can offer potential benefits for smaller niche players. Whilst the potential for blockbusters is limited, government grants can lead to assured revenues, without the need for extensive detailing activities. In addition, the publicity surrounding platform technologies arising from government purchase of such products can give a major boost to small players at minimal cost. The low incidence of rare and emerging infectious diseases, such as West Nile disease, present market opportunities for prophylactics, if not for novel therapeutics. Given the probable reluctance of government agencies to reimburse prophylactic products in non-risk groups, there is potential to introduce schemes such as co- or full- patient payment. Reasons to Purchase Identify the commercial potential of entering into biodefense and emerging disease niche markets Understand how compulsory licensing could act as a major disincentive to expanding the indication of existing products to meet bioterrorist threats. DRIVERS AND TRENDS The keynote lectures at the 42nd ICAAC 2002 focused on emerging and re-emerging infections and the increasing threat of bioterrorism. The events of September 2001 highlighted the fact that Western civilization is not unassailable, and that the unpredictability of terrorist attacks are a realistic threat to the lives and economies of target countries. There has, therefore, been increasing government activity to prepare for the threat of further such attacks. The market for biodefense is guaranteed but limited. There are, however, a number of factors that could attract smaller companies to enter the market. Likewise, the market for emerging infections, such as West Nile Virus, is highly specific. This brief explores the commercial opportunities to be found within both markets. BIOTERRORISM What is the current market potential for biodefense products? What are the risks involved in market entrance? This section provides: An overview of the pathogens that the CDC considers to be the most dangerous agents that could be used as bioterrorist weapons The commercial opportunities for companies looking to enter this market are discussed, alongside the risks involved in the development of biodefense agents Anthrax and smallpox are explored in greater detail, as the two agents that the CDC is currently giving highest priority to, including an assessment of current and future product pipelines. EMERGING AND RE-EMERGING INFECTIONS Emerging and re-emerging diseases can pose a threat to entire populations. The most recent emerging disease to hit the headlines in the US is West Nile Virus (WNV). This section of the brief summarizes the epidemiology of the disease, and current and future product pipelines. The potential strategies to maximize revenue gained from entering this market are also discussed. In addition to WNV, the potential threats of a major flu pandemic, and current strategies that are in place to deal with this eventuality are discussed. ACTION POINTS Understand the key themes arising from the 42nd ICAAC conference Identify the commercial potential of entering into the biodefense market Pinpoint current economically important emerging infections DATASETS Table 1: CDC classification of potential agents of bioterrorism Table 2: Potential agents of bioterrorist attacks Table 3: Current anthrax products for treatment and prophylaxis Table 4: Pipeline products for anthrax treatment and prophylaxis Table 5: Current smallpox vaccines in development Table 6: Companies developing West Nile Virus prophylaxis Table 7: Currently manufactured influenza vaccines Table 8: Marketed products used for influenza treatment Figure 1: Influenza Pandemics 1900-2000 AbstractThe Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) is the world's premier meeting on infectious diseases and antimicrobial agents, organized by the American Society for Microbiology. This Brief discusses some of the keynote lectures at the 42nd ICAAC 2002, focusing on emerging and re-emerging infections and the increasing threat of bioterrorism.The key pathogens and bioterrorism threats are identified. Incentives for developing new products for biodefense are discussed.Emerging and re-emerging infections are profiled. Key commercial opportunities to develop and commercialize relevant products are identified.The bioterrorism-related pharmaceutical market can offer potential benefits for smaller niche players. Whilst the potential for blockbusters is limited, government grants can lead to assured revenues, without the need for extensive detailing activities. In addition, the publicity surrounding platform technologies arising from government purchase of such products can give a major boost to small players at minimal cost.The low incidence of rare and emerging infectious diseases, such as West Nile disease, present market opportunities for prophylactics, if not for novel therapeutics. Given the probable reluctance of government agencies to reimburse prophylactic products in non-risk groups, there is potential to introduce schemes such as co- or full- patient payment.Identify the commercial potential of entering into biodefense and emerging disease niche marketsUnderstand how compulsory licensing could act as a major disincentive to expanding the indication of existing products to meet bioterrorist threats.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||